Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Ouellet

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Expert Opinion on Drug Safety|February 24, 2010
Benefit-risk assessment: the use of clinical utility indexDaniele Ouellet
Expert Review of Clinical Pharmacology|September 25, 2023
Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunitiesJin Niu, Weirong Wang, Daniele Ouellet
Advanced Drug Delivery Reviews|December 19, 2024
Applications of pharmacometrics in drug developmentYuan Xiong, Mahesh N Samtani, Daniele Ouellet
Journal of Pharmacokinetics and Pharmacodynamics|January 17, 2023
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitisChuanpu Hu, Marion Vetter, An Vermeulen, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 9, 2020
Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID-19 Clinical TrialsJim H Hughes, Kevin Sweeney, Sima Ahadieh, et al.
Journal of Clinical Pharmacology|October 12, 2019
Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study AnalysisLilian Y Li, Yue Guo, Martha Gonzalez, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 20, 2019
Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approachYue Guo, Nahor Haddish-Berhane, Hong Xie, et al.
Journal of Clinical Pharmacology|July 29, 2010
Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpuraEkaterina Gibiansky, Jianping Zhang, Daphne Williams, et al.
Pharmaceutical Research|June 18, 2011
Modeling sleep data for a new drug in development using markov mixed-effects modelsMaria C Kjellsson, Daniele Ouellet, Brian Corrigan, et al.
Journal of Clinical Pharmacology|November 18, 2005
Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal womenDoina Roman, Candace Bramson, Daniele Ouellet, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Expert Opinion on Drug Safety|February 24, 2010
Benefit-risk assessment: the use of clinical utility indexDaniele Ouellet
Expert Review of Clinical Pharmacology|September 25, 2023
Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunitiesJin Niu, Weirong Wang, Daniele Ouellet
Advanced Drug Delivery Reviews|December 19, 2024
Applications of pharmacometrics in drug developmentYuan Xiong, Mahesh N Samtani, Daniele Ouellet
Journal of Pharmacokinetics and Pharmacodynamics|January 17, 2023
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitisChuanpu Hu, Marion Vetter, An Vermeulen, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 9, 2020
Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID-19 Clinical TrialsJim H Hughes, Kevin Sweeney, Sima Ahadieh, et al.
Journal of Clinical Pharmacology|October 12, 2019
Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study AnalysisLilian Y Li, Yue Guo, Martha Gonzalez, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 20, 2019
Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approachYue Guo, Nahor Haddish-Berhane, Hong Xie, et al.
Journal of Clinical Pharmacology|July 29, 2010
Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpuraEkaterina Gibiansky, Jianping Zhang, Daphne Williams, et al.
Pharmaceutical Research|June 18, 2011
Modeling sleep data for a new drug in development using markov mixed-effects modelsMaria C Kjellsson, Daniele Ouellet, Brian Corrigan, et al.
Journal of Clinical Pharmacology|November 18, 2005
Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal womenDoina Roman, Candace Bramson, Daniele Ouellet, et al.
Pageof 7